Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 2001

View Archived Issues

Novel process for synthesis of HIV protease inhibitors offered for licensing by NIH

Enzon reports Q1 2001 highlights

Neose Technologies and BMS amend cancer vaccine collaboration

VitaResc's VTR-PHP NO scavenger enters phase III testing

NIH licensing opportunity: immunogenicity-enhancing modifications of HIV env, gag and pol

Rapid and sustained symptom relief experienced by majority of IBS patients on tegaserod

Licensing opportunity from NIH: synthetic peptide vaccines elicit protective mucosal CTL response

Small molecule from Point Therapeutics stimulates hematopoiesis, advances in clinical testing

Antimicrobial magainin peptides offered for licensing by NIH

Hybridon and Isis exchange licenses to antisense-related technologies

NO scavenger AMD-6221 enhances cardiac allograft survival, particularly in combination with CsA

DDW presentations describe pharmacological profile of Z-360, a new gastrin antagonist

AnorMED halts development of AMD-3100 for treatment of HIV infection

FDA advisory committee unanimously recommends approval of Natrecor

Combination NO scavenger + ciclosporin prolongs rat cardiac allograft survival

Company Profile: OmniScience Pharmaceuticals

Avicine may be as effective as traditional chemotherapy in pancreatic cancer

FDA approves King's NDA for Levoxyl

First human results for rhAngiostatin support its further development

Company Profile: Lorantis

Antimicrobial substance produced by fungal species identified at Fujisawa

New compounds for AIDS in development at Takeda

Inhibitors of Abeta production discovered at DuPont

Pfizer describes potent new phosphodiesterase inhibitors and potential therapeutic uses

Hisamitsu's newest substance P antagonists presented in recent patent

Inhibitors of IL-6 production particularly useful in inflammatory diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...